288 related articles for article (PubMed ID: 27215400)
1. Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.
Cernomaz AT; Macovei II; Pavel I; Grigoriu C; Marinca M; Baty F; Peter S; Zonda R; Brutsche M; Grigoriu B
BMC Pulm Med; 2016 May; 16(1):88. PubMed ID: 27215400
[TBL] [Abstract][Full Text] [Related]
2. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
3. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
[TBL] [Abstract][Full Text] [Related]
4. Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas.
Tønnesen E; Lade-Keller J; Stougaard M
Hum Pathol; 2021 Sep; 115():67-75. PubMed ID: 34153308
[TBL] [Abstract][Full Text] [Related]
5. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
[TBL] [Abstract][Full Text] [Related]
7. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
8. Detection of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma: Comparing Cobas 4800 EGFR Assay With Sanger Bidirectional Sequencing.
Ardakani NM; Giardina T; Grieu-Iacopetta F; Tesfai Y; Carrello A; Taylor J; Robinson C; Spagnolo D; Amanuel B
Clin Lung Cancer; 2016 Sep; 17(5):e113-e119. PubMed ID: 26961433
[TBL] [Abstract][Full Text] [Related]
9. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
10. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing.
Buttitta F; Felicioni L; Del Grammastro M; Filice G; Di Lorito A; Malatesta S; Viola P; Centi I; D'Antuono T; Zappacosta R; Rosini S; Cuccurullo F; Marchetti A
Clin Cancer Res; 2013 Feb; 19(3):691-8. PubMed ID: 23243218
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.
Xie F; Zheng X; Mao X; Zhao R; Ye J; Zhang Y; Sun J
Ann Thorac Surg; 2019 Jul; 108(1):219-226. PubMed ID: 30885850
[TBL] [Abstract][Full Text] [Related]
13. Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study.
Min KW; Kim WS; Jang SJ; Choi YD; Chang S; Jung SH; Kim L; Roh MS; Lee CS; Shim JW; Kim MJ; Lee GK;
QJM; 2016 Mar; 109(3):167-73. PubMed ID: 26031706
[TBL] [Abstract][Full Text] [Related]
14. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
[TBL] [Abstract][Full Text] [Related]
15. Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma.
Paliogiannis P; Attene F; Cossu A; Defraia E; Porcu G; Carta A; Sotgiu MI; Pazzola A; Cordero L; Capelli F; Fadda GM; Ortu S; Sotgiu G; Palomba G; Sini MC; Palmieri G; Colombino M
Mol Med Rep; 2015 Jul; 12(1):187-91. PubMed ID: 25683726
[TBL] [Abstract][Full Text] [Related]
16. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and treatment outcomes of lung adenocarcinomas with discrepant EGFR mutation testing results derived from PCR-direct sequencing and real-time PCR-based assays.
Chiu CH; Ho HL; Chiang CL; Lin SF; Ma HH; Chuang YT; Lin KY; Tsai CM; Chou TY
J Thorac Oncol; 2014 Jan; 9(1):91-6. PubMed ID: 24346097
[TBL] [Abstract][Full Text] [Related]
19. Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing.
Liang C; Wu Z; Gan X; Liu Y; You Y; Liu C; Zhou C; Liang Y; Mo H; Chen AM; Zhang J
Yonsei Med J; 2018 Jan; 59(1):13-19. PubMed ID: 29214771
[TBL] [Abstract][Full Text] [Related]
20. Mutation Profile of Resected
Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
